Table 1.
Programmed death-ligand 1 and programmed cell death protein 1 inhibitors in development
| Investigational Agent | Target | Tumor Type(s) | Highest Phase |
|---|---|---|---|
| BMS936559 | PD-L1 | Advanced solid tumors, including melanoma | 1 (multiple) |
| MEDI4736 | PD-L1 | NSCLC, SCCHN, GBM, and other advanced solid tumors | 3 (NSCLC) |
| MPDL3280A | PD-L1 | Bladder cancer, NSCLC, renal cell carcinoma, and other advanced solid tumors | 3 (NSCLC) |
| MSB0010718C | PD-L1 | Advanced solid tumors | 2 (Merkel cell) |
| AMP224 | PD-1 | Advanced solid tumors, CRC | 1 (advanced solid tumors, CRC) |
| AMP514/MEDI0680 | PD-1 | Advanced malignancies, aggressive B-cell lymphomas | 2 (aggressive B-cell lymphomas) |
| Pidilizumab | PD-1 | Multiple myeloma, GBM, lymphoma | 2 (lymphoma) |
| Pembrolizumab | PD-1 | NSCLC, GBM, SCCHN, pancreatic cancer, renal cell cancer, other advanced solid tumors, lymphoma | Marketed (metastatic melanoma) |
| Nivolumab | PD-1 | CRC, GBM, HCC, NSCLC, SCCHN, SCLC, breast cancer, bladder cancer, gastric cancer, melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, renal cancer, lymphoma (HL, NHL) | Marketed (metastatic melanoma, NSCLC) |
Abbreviations: CRC, colorectal cancer; GBM, glioblastoma; HCC, hepatocellular cancer; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; NSCLC, non–small-cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1;SCCHN, squamous cell cancer of the head and neck; SCLC, small-cell lung cancer.